secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001104659-23-041009
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio enters $50M ATM equity offering with BofA and ThinkEquity
---------------------------------------------------------------------

- Up to $50M of common stock may be sold through BofA Securities and ThinkEquity as sales agents.
- Sales agents will receive commission up to 2.0% of gross proceeds; customary indemnification provided.
- Shares sold at market prices in ordinary brokers' transactions; no minimum obligation to sell.
- Offering is made under existing shelf registration statement (File 333-252625) and prospectus supplement dated March 31, 2023.
- Agreement may be terminated by either party; no assurance of any sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923041009/0001104659-23-041009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923041009/tm2311180d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-041009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer